Enliven Therapeutics, Inc. Common Stock

ELVN XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

2.2B

Short interest (May 15)

8.4%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.41%

↑ 7.8%

Available Shares

300K

↓ 20.0%

Price Chart

Company Overview

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001672619

Asset Type: CS

Market Data

Market Cap: $2,163,343,681

Employees: 61

Status: Active

Short Interest

Current Borrow Fee 0.41%

Range: 0.40% - 0.41%

Available Shares 300K

Range: 300K - 300K

Recent Changes

Fee Change: ↓ 0.0%

Available Change: ↑ 8.3%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime